Haridwar Today

Diffuse Cutaneous Systemic Sclerosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Diffuse Cutaneous Systemic Sclerosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

February 07
01:01 2023
Diffuse Cutaneous Systemic Sclerosis Pipeline Insights
DelveInsight’s, “Diffuse Cutaneous Systemic Sclerosis- Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Diffuse Cutaneous Systemic Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

United States, Nevada, Las Vegas, DelveInsight’s Diffuse Cutaneous Systemic Sclerosis Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Diffuse Cutaneous Systemic Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diffuse Cutaneous Systemic Sclerosis pipeline domain.

Key Takeaways from the Diffuse Cutaneous Systemic Sclerosis Pipeline Report

  • Over 15+ Diffuse Cutaneous Systemic Sclerosis pipeline therapies are in various stages of development, and their anticipated acceptance in the Diffuse Cutaneous Systemic Sclerosis market would significantly increase market revenue. 
  • Leading Diffuse Cutaneous Systemic Sclerosis companies developing novel drug candidates to improve the Diffuse Cutaneous Systemic Sclerosis treatment landscape include Talaris Therapeutics, Kadmon Pharmaceuticals, and others.
  • Promising Diffuse Cutaneous Systemic Sclerosis pipeline therapies in various stages of development include FCR 001, Belumosudil, and others.

Diffuse Cutaneous Systemic Sclerosis Overview

Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of systemic scleroderma (systemic sclerosis) and is characterized by skin hardening (fibrosis) and problems in many organs of the body. The prevalence is estimated at about 1/25,000 adults. Women are predominantly affected. The disease usually manifests at between 40 and 50 years of age. Pediatric onset can occur but is extremely rare. Raynaud’s phenomenon is often the first sign of the disease. The other signs usually appear a few months later. Skin hardening first occurs on the fingers and face, but rapidly becomes generalized. Telangiectasias are sometimes present on the thorax, face, lips, tongue, and fingers. Tendon friction rubs are observed. Esophageal dysmotility is common and provokes gastroesophageal reflux and sometimes dysphagia. Gastrointestinal malabsorption and dysmotility may also be present and are associated with weight loss, vomiting, diarrhea or occlusion. Dry mouth and dental involvement can occur. Arthralgias and acroosteolysis are frequent. 

Diffuse Cutaneous Systemic Sclerosis Pipeline Analysis: Drug Profile

FCR 001: Talaris Therapeutics

FCR001 is an investigational, allogeneic cell therapy developed by Talaris Therapeutics to induce or restore patients’ immune tolerance. FCR001 builds on over 30 years of research by the company’s founder, Dr. Suzanne Ildstad, into the means by which durable immune tolerance can be induced in a patient who receives a transplanted organ or can be restored in patients with certain immune-mediated or blood disorders. FCR001 has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Diffuse Cutaneous Systemic Sclerosis.

Discover more about the emerging Diffuse Cutaneous Systemic Sclerosis drugs @ Diffuse Cutaneous Systemic Sclerosis Treatment Drugs

Diffuse Cutaneous Systemic Sclerosis Key Companies

  • Talaris Therapeutics
  • Kadmon Pharmaceuticals

Diffuse Cutaneous Systemic Sclerosis Pipeline Therapies

  • FCR 001
  • Belumosudil

Diffuse Cutaneous Systemic Sclerosis Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Diffuse Cutaneous Systemic Sclerosis Pipeline Report 

  • Coverage: Global 
  • Key Diffuse Cutaneous Systemic Sclerosis Companies: Talaris Therapeutics, Kadmon Pharmaceuticals, and others
  • Key Diffuse Cutaneous Systemic Sclerosis Pipeline Therapies: FCR 001, Belumosudil, and others

Find out more about the Diffuse Cutaneous Systemic Sclerosis treatment options in development @ Diffuse Cutaneous Systemic Sclerosis Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Recent Posts

Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

Read Full Article

Categories